CCL4 was particularly prominent throughout our analysis, being also observed at the highest levels in patients with no adverse features (alongside CCL3, IL-1α, and IL-12/IL-23p40), elevated in patients with high tumor lymphocyte infiltration and negatively associated with serosal invasion and pathologic tumor stage. The gene discussed is CCL3; the disease is neoplasm.